Share
Laura Hamill
Jazz Pharmaceuticals plc, has announced the election of Laura Hamill to its Board of Directors at the company’s Annual General Meeting.
Ms. Hamill, a seasoned executive with 35 years in the pharmaceutical industry, brings extensive global commercial operations and leadership experience to Jazz's Board. Her appointment follows the earlier addition of Patrick Kennedy and is part of Jazz’s ongoing commitment to Board renewal. In addition to Ms. Hamill and Mr. Kennedy, shareholders also re-elected Kenneth O'Keefe and Mark Smith for additional terms.
“We are thrilled to welcome Laura to our Board,” said Bruce Cozadd, Chairperson and CEO of Jazz Pharmaceuticals. “Her deep commercial and industry expertise, combined with her impressive track record in leading multinational companies, aligns perfectly with Jazz’s mission to create shareholder value. Laura’s background will significantly enhance our Board’s capabilities as we continue to focus on transforming the lives of patients and their families.”
Ms. Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, Inc., from 2018 to 2019. Prior to that role, she held various executive positions at Amgen Inc. from 2002 to 2018, including Senior Vice President of U.S. Commercial Operations and Senior Vice President of the Intercontinental Region. Currently, Ms. Hamill serves on the boards of Y-mAbs Therapeutics Inc., BB Biotech, and Unchained Labs, a privately held company.
“I am impressed by the global talent driving Jazz’s success,” said Ms. Hamill. “I am eager to collaborate with my fellow Board members and the company's management to guide Jazz’s future growth, deliver sustained value to our shareholders, and make a meaningful impact on patients.”
Effective today, Peter Gray and Catherine Sohn, Pharm.D., have retired from the Jazz Board. The Board now consists of twelve directors, with five having been appointed in the past five years.
“We extend our deepest thanks to Cathy and Peter for their exceptional service and dedication to Jazz,” added Cozadd. “Their contributions have been invaluable in our transformation and growth, and we wish them well as they step down from the Board.”
